Quantitation of trace levels of DNA released from disrupted Adeno-associated virus gene therapy vectors

Bee, J., O'Berry, K., Zhang, Y., et al.

Journal of Pharmaceutical Sciences 2021, doi: 10.1016/j.xphs.2021.06.010

Abstract

Thermal shift assays measure the stability of macromolecules and macromolecular assemblies as a function of temperature. The Particle Stability Thermal Release Assay (PaSTRy) of picornaviruses is based on probes becoming strongly fluorescent upon binding to hydrophobic patches of the protein capsid (e.g., SYPRO Orange) or to the viral RNA genome (e.g., SYTO-82) that become exposed upon heating virus particles. PaSTRy has been exploited for studying the stability of viral mutants, viral uncoating, and the effect of capsid-stabilizing compounds. While the results were usually robust, the thermal shift assay with SYPRO Orange is sensitive to surfactants and EDTA and failed at least to correctly report the effect of excipients on an inactivated poliovirus 3 vaccine. Furthermore, interactions between the probe and capsid-binding antivirals as well as mutual competition for binding sites cannot be excluded. To overcome these caveats, we assessed differential scanning fluorimetry with a nanoDSF device as a label-free alternative. NanoDSF monitors the changes in the intrinsic tryptophan fluorescence (ITF) resulting from alterations of the 3D-structure of proteins as a function of the temperature. Using rhinovirus A2 as a model, we demonstrate that nanoDSF is well suited for recording the temperature-dependence of conformational changes associated with viral uncoating with minute amounts of sample. We compare it with orthogonal methods and correlate the increase in viral RNA exposure with PaSTRy measurements. Importantly, nanoDSF correctly identified the thermal stabilization of RV-A2 by pleconaril, a prototypic pocket-binding antiviral compound. NanoDSF is thus a label-free, high throughput-customizable, attractive alternative for the discovery of capsid-binding compounds impacting on viral stability.

View Publication

Topics: Prometheus, nanoDSF, Gene Therapy, Publications

Previous Article
Methods Matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors
Methods Matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors

Up next
Practical strategies for overcoming challenges in the development of AAV vectors for gene therapy
Practical strategies for overcoming challenges in the development of AAV vectors for gene therapy

Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. W...

Trying to develop safe and effective gene therapies?

Biophysical methods can help.

Find out how
×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!